Located in Northbrook, Illinois, Horizon Pharma is a biopharmaceutical company that commercializes innovative medicine that targets the unmet therapeutic needs in arthritis, pain and inflammatory diseases. Today, Horizon took another step forward with the announcement they have appointed industry veterans Michael Grey and Ronald Pauli to their Board of Directors.
Michael Grey received his bachelor’s degree in chemistry from the University of Nottingham in the United Kingdom. Since then, Grey has had an impressive career. Grey currently serves as president and chief executive officer at Lumena Pharmaceuticals, Inc. In a career that has spanned more than 3 decades, he has held senior positions at a number of other companies, including president and chief executive officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), president and chief executive officer of Trega Biosciences, Inc. (sold to Lion Bioscience in 2001) and president of BioChem Therapeutic Inc.
Ronald Pauli received a bachelor’s degree in accounting from Michigan State University and went on to earn a master’s degree in finance from Walsh College. Pauli has led an illustrious career and is currently chief business officer at Sagent Pharmaceuticals, Inc., where he was recently promoted from his role as chief financial officer. As CFO, he played a key role in Sagent’s recent initial public offering. In addition, Mr. Pauli has held senior positions at a number of biopharmaceutical companies, including chief financial officer at NeoPharm, Inc. and corporate controller and interim chief financial officer at Abraxis BioScience, Inc., formerly American Pharmaceutical Partners, Inc. Mr. Pauli previously served as corporate controller for Applied Power, Inc. and R.P. Scherer Corporation and also held multiple finance positions at Kmart Corporation.
The appointments of Grey and Pauli come on the heels of Dr. Peter Johann resigning from the Horizon Board of Director’s after an impactful career with the company.
Leading the way at Horizon is Timothy P. Walbert whom serves as the Chairman, President and CEO of the Company. Walbert stated, “We are pleased to welcome Mike and Ron to our board. Their extensive pharma and biopharmaceutical experience in business development, finance and building companies will be an asset to our Board and beneficial to Horizon’s future growth.”
In reference to the resignation of Dr. Johann, Walbert commented, “On behalf of the Board of Directors of Horizon, I would like to thank Peter for his contributions to the Company’s journey to date and we wish him well in his endeavors.”
Currently, Horizon Pharma, Inc. is trading in the $7.48 range. To learn more about the company as a whole, visit their corporate website at: horizonpharma.com
Please see disclaimer on the MissionIR website www.missionir.com/disclaimer.html